ramucirumab,pembrolizumab
eli lilly,merck
['ramucirumab', 'lung-map', 'lung']
simultaneous publication and presentation at asco. lung-map is a phase ii trial that asks the question what to do after progression on previous io therapy and platinum based chemotherapy in lung cancer. patients were randomly assigned to receive ramucirumab + 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"